CA2711739A1 - Multi-function catheter and use thereof - Google Patents
Multi-function catheter and use thereof Download PDFInfo
- Publication number
- CA2711739A1 CA2711739A1 CA2711739A CA2711739A CA2711739A1 CA 2711739 A1 CA2711739 A1 CA 2711739A1 CA 2711739 A CA2711739 A CA 2711739A CA 2711739 A CA2711739 A CA 2711739A CA 2711739 A1 CA2711739 A1 CA 2711739A1
- Authority
- CA
- Canada
- Prior art keywords
- catheter
- agent
- lumen
- treatment
- balloons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 claims abstract description 133
- 239000000463 material Substances 0.000 claims abstract description 88
- 238000000034 method Methods 0.000 claims abstract description 63
- 239000013060 biological fluid Substances 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 66
- 206010028980 Neoplasm Diseases 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 239000012829 chemotherapy agent Substances 0.000 claims description 17
- 239000012216 imaging agent Substances 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 10
- 230000003073 embolic effect Effects 0.000 claims description 6
- 239000002872 contrast media Substances 0.000 claims description 5
- 229920001195 polyisoprene Polymers 0.000 claims description 3
- 239000008280 blood Substances 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 19
- 206010002329 Aneurysm Diseases 0.000 description 32
- 239000012530 fluid Substances 0.000 description 25
- 238000001802 infusion Methods 0.000 description 21
- 210000001367 artery Anatomy 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- -1 for example Polymers 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 208000031481 Pathologic Constriction Diseases 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000001125 extrusion Methods 0.000 description 7
- 238000011065 in-situ storage Methods 0.000 description 7
- 230000036262 stenosis Effects 0.000 description 7
- 208000037804 stenosis Diseases 0.000 description 7
- 238000002399 angioplasty Methods 0.000 description 6
- 208000037803 restenosis Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000036770 blood supply Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004323 axial length Effects 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- DSUFPYCILZXJFF-UHFFFAOYSA-N 4-[[4-[[4-(pentoxycarbonylamino)cyclohexyl]methyl]cyclohexyl]carbamoyloxy]butyl n-[4-[[4-(butoxycarbonylamino)cyclohexyl]methyl]cyclohexyl]carbamate Chemical compound C1CC(NC(=O)OCCCCC)CCC1CC1CCC(NC(=O)OCCCCOC(=O)NC2CCC(CC3CCC(CC3)NC(=O)OCCCC)CC2)CC1 DSUFPYCILZXJFF-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- YIVJZNGAASQVEM-UHFFFAOYSA-N Lauroyl peroxide Chemical compound CCCCCCCCCCCC(=O)OOC(=O)CCCCCCCCCCC YIVJZNGAASQVEM-UHFFFAOYSA-N 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 208000004717 Ruptured Aneurysm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006230 acetylene black Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000011157 advanced composite material Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium peroxydisulfate Substances [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 1
- VAZSKTXWXKYQJF-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)OOS([O-])=O VAZSKTXWXKYQJF-UHFFFAOYSA-N 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 108010087173 bile salt-stimulated lipase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FHTQCUNSKSWOHF-UHFFFAOYSA-N ethyl carbamate;silicon Chemical compound [Si].CCOC(N)=O FHTQCUNSKSWOHF-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000030843 hydrosalpinx Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QHDRKFYEGYYIIK-UHFFFAOYSA-N isovaleronitrile Chemical compound CC(C)CC#N QHDRKFYEGYYIIK-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical compound [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920001291 polyvinyl halide Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1011—Multiple balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/958—Inflatable balloons for placing stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1095—Balloon catheters with special features or adapted for special applications with perfusion means for enabling blood circulation while the balloon is in an inflated state or in a deflated state, e.g. permanent by-pass within catheter shaft
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biophysics (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cardiology (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/971,859 | 2008-01-09 | ||
| US11/971,859 US8062251B2 (en) | 2002-02-01 | 2008-01-09 | Multi-function catheter and use thereof |
| PCT/US2009/030434 WO2009089343A1 (en) | 2008-01-09 | 2009-01-08 | Multi-function catheter and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2711739A1 true CA2711739A1 (en) | 2009-07-16 |
Family
ID=40853452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2711739A Abandoned CA2711739A1 (en) | 2008-01-09 | 2009-01-08 | Multi-function catheter and use thereof |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8062251B2 (enExample) |
| EP (1) | EP2240231A4 (enExample) |
| JP (1) | JP2011509158A (enExample) |
| CA (1) | CA2711739A1 (enExample) |
| WO (1) | WO2009089343A1 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6863683B2 (en) | 2001-09-19 | 2005-03-08 | Abbott Laboratoris Vascular Entities Limited | Cold-molding process for loading a stent onto a stent delivery system |
| US8062251B2 (en) * | 2002-02-01 | 2011-11-22 | Vascular Designs, Inc. | Multi-function catheter and use thereof |
| US20050267407A1 (en) * | 2002-02-01 | 2005-12-01 | Vascular Designs, Inc. | Multi-function catheter and use thereof |
| CA2476263C (en) * | 2002-02-01 | 2012-08-21 | Robert J. Goldman | Multi-function catheter and use thereof |
| US8333000B2 (en) | 2006-06-19 | 2012-12-18 | Advanced Cardiovascular Systems, Inc. | Methods for improving stent retention on a balloon catheter |
| US8236039B2 (en) * | 2007-12-21 | 2012-08-07 | Abbott Laboratories | Vena cava filter having wall contacts |
| EP3093039A1 (en) | 2008-11-03 | 2016-11-16 | Advanced Catheter Therapies, Inc. | Occlusion perfusion catheter |
| US8226601B2 (en) * | 2008-11-12 | 2012-07-24 | Sanovas, Inc. | Resector balloon system |
| US8540667B2 (en) * | 2008-11-12 | 2013-09-24 | Sanovas, Inc. | Multi-balloon catheter for extravasated drug delivery |
| EP2196174B1 (en) | 2008-12-12 | 2014-02-26 | Abbott Laboratories Vascular Enterprises Limited | Process for loading a stent onto a stent delivery system |
| EP2322118B1 (en) * | 2009-11-11 | 2012-12-19 | Abbott Laboratories Vascular Enterprises Limited | Medical devices for medical device delivery systems |
| EP2493419B1 (en) * | 2009-10-30 | 2016-05-04 | Abbott Laboratories Vascular Enterprises Limited | Medical device for treatment of a lumen |
| US20110106234A1 (en) * | 2009-10-30 | 2011-05-05 | Axel Grandt | Interluminal medical treatment devices and methods |
| ES2828722T3 (es) | 2009-12-02 | 2021-05-27 | Renovorx Inc | Dispositivos y kits para entrega de materiales terapéuticos a un páncreas |
| US9539081B2 (en) | 2009-12-02 | 2017-01-10 | Surefire Medical, Inc. | Method of operating a microvalve protection device |
| US9457171B2 (en) | 2009-12-02 | 2016-10-04 | Renovorx, Inc. | Devices, methods and kits for delivery of therapeutic materials to a target artery |
| US10512761B2 (en) | 2009-12-02 | 2019-12-24 | Renovorx, Inc. | Methods for delivery of therapeutic materials to treat pancreatic cancer |
| US8348890B2 (en) | 2011-03-01 | 2013-01-08 | Sanovas, Inc. | Nested balloon catheter for localized drug delivery |
| US20160074581A1 (en) | 2014-09-17 | 2016-03-17 | Lawrence J. Gerrans | Modulated Drug Delivery |
| US10898693B2 (en) | 2011-03-01 | 2021-01-26 | Sanovas Intellectual Property, Llc | Nasal delivery of agents with nested balloon catheter |
| US8597239B2 (en) * | 2011-03-01 | 2013-12-03 | Sanovas, Inc. | Abrading balloon catheter for extravasated drug delivery |
| US9180281B2 (en) | 2011-04-08 | 2015-11-10 | Sanovas, Inc. | Adjustable balloon catheter for extravasated drug delivery |
| US20120259401A1 (en) | 2011-04-08 | 2012-10-11 | Gerrans Lawrence J | Balloon catheter for launching drug delivery device |
| US9205234B2 (en) | 2012-03-27 | 2015-12-08 | Terry D. Hardin | Device for a biological treatment |
| JP6301926B2 (ja) | 2012-08-09 | 2018-03-28 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | カテーテル、カテーテルシステム、及び組織構造を刺通する方法 |
| US12208224B2 (en) | 2012-11-02 | 2025-01-28 | Neurotronic, Inc. | Chemical ablation and method of treatment for various diseases |
| EP4230162B1 (en) | 2012-11-02 | 2024-10-09 | Neurotronic, Inc. | Chemical ablation formulations for various diseases |
| CN105530986A (zh) | 2013-05-08 | 2016-04-27 | 埃姆博尔克斯公司 | 用于经血管肿瘤栓塞的具有综合流量调节的设备及方法 |
| US9844383B2 (en) | 2013-05-08 | 2017-12-19 | Embolx, Inc. | Devices and methods for low pressure tumor embolization |
| WO2014197362A1 (en) | 2013-06-03 | 2014-12-11 | Ramtin Agah | Devices, methods and kits for delivery of therapeutic materials to a pancreas |
| JP6661539B2 (ja) | 2013-12-20 | 2020-03-11 | テルモ株式会社 | 血管閉鎖 |
| WO2015103574A1 (en) | 2014-01-06 | 2015-07-09 | Iowa Approach Inc. | Apparatus and methods for renal denervation ablation |
| US9968740B2 (en) | 2014-03-25 | 2018-05-15 | Surefire Medical, Inc. | Closed tip dynamic microvalve protection device |
| EP4238521B1 (en) | 2014-05-07 | 2025-10-15 | Boston Scientific Scimed, Inc. | Apparatus for selective tissue ablation |
| WO2015175944A1 (en) | 2014-05-16 | 2015-11-19 | Gary Long | Methods and apparatus for multi-catheter tissue ablation |
| WO2015192027A1 (en) | 2014-06-12 | 2015-12-17 | Iowa Approach Inc. | Method and apparatus for rapid and selective transurethral tissue ablation |
| WO2015192018A1 (en) | 2014-06-12 | 2015-12-17 | Iowa Approach Inc. | Method and apparatus for rapid and selective tissue ablation with cooling |
| WO2016060983A1 (en) | 2014-10-14 | 2016-04-21 | Iowa Approach Inc. | Method and apparatus for rapid and safe pulmonary vein cardiac ablation |
| EP3212274A4 (en) | 2014-10-30 | 2018-06-27 | Neurotronic, Inc. | Chemical ablation and method of treatment for various diseases |
| US20160287839A1 (en) | 2015-03-31 | 2016-10-06 | Surefire Medical, Inc. | Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment |
| US12144541B2 (en) | 2016-01-05 | 2024-11-19 | Boston Scientific Scimed, Inc. | Systems, apparatuses and methods for delivery of ablative energy to tissue |
| US10130423B1 (en) | 2017-07-06 | 2018-11-20 | Farapulse, Inc. | Systems, devices, and methods for focal ablation |
| US20170189097A1 (en) | 2016-01-05 | 2017-07-06 | Iowa Approach Inc. | Systems, apparatuses and methods for delivery of ablative energy to tissue |
| US10172673B2 (en) | 2016-01-05 | 2019-01-08 | Farapulse, Inc. | Systems devices, and methods for delivery of pulsed electric field ablative energy to endocardial tissue |
| US10660702B2 (en) | 2016-01-05 | 2020-05-26 | Farapulse, Inc. | Systems, devices, and methods for focal ablation |
| US9550046B1 (en) | 2016-02-16 | 2017-01-24 | Embolx, Inc. | Balloon catheter and methods of fabrication and use |
| US12268824B2 (en) | 2018-07-27 | 2025-04-08 | Embolx, Inc. | Shaped catheter tip for tracking over a guidewire through turns in the vasculature |
| US11464948B2 (en) | 2016-02-16 | 2022-10-11 | Embolx, Inc. | Balloon catheters and methods of manufacture and use |
| US10350382B1 (en) | 2018-06-08 | 2019-07-16 | Embolx, Inc. | High torque catheter and methods of manufacture |
| US10588503B2 (en) | 2016-03-29 | 2020-03-17 | Terumo Kabushiki Kaisha | Methods and medical elongate bodies |
| EP3471631A4 (en) | 2016-06-16 | 2020-03-04 | Farapulse, Inc. | Systems, apparatuses, and methods for guide wire delivery |
| US11400263B1 (en) | 2016-09-19 | 2022-08-02 | Trisalus Life Sciences, Inc. | System and method for selective pressure-controlled therapeutic delivery |
| US10780250B1 (en) | 2016-09-19 | 2020-09-22 | Surefire Medical, Inc. | System and method for selective pressure-controlled therapeutic delivery |
| US10588636B2 (en) | 2017-03-20 | 2020-03-17 | Surefire Medical, Inc. | Dynamic reconfigurable microvalve protection device |
| US9987081B1 (en) | 2017-04-27 | 2018-06-05 | Iowa Approach, Inc. | Systems, devices, and methods for signal generation |
| US10617867B2 (en) | 2017-04-28 | 2020-04-14 | Farapulse, Inc. | Systems, devices, and methods for delivery of pulsed electric field ablative energy to esophageal tissue |
| US10695543B2 (en) | 2017-05-18 | 2020-06-30 | Renovorx, Inc. | Methods for treating cancerous tumors |
| US12290564B2 (en) | 2017-05-18 | 2025-05-06 | Renovorx, Inc. | Methods and apparatuses for treating tumors |
| US11052224B2 (en) | 2017-05-18 | 2021-07-06 | Renovorx, Inc. | Methods for treating cancerous tumors |
| JP7293132B2 (ja) | 2017-05-25 | 2023-06-19 | テルモ株式会社 | 接着閉塞システム |
| EP3681391A1 (en) | 2017-09-12 | 2020-07-22 | Farapulse, Inc. | Systems, apparatuses, and methods for ventricular focal ablation |
| JP2019097596A (ja) * | 2017-11-28 | 2019-06-24 | 株式会社カネカ | バルーンカテーテル |
| WO2019157359A1 (en) | 2018-02-08 | 2019-08-15 | Farapulse, Inc. | Method and apparatus for controlled delivery of pulsed electric field ablative energy to tissue |
| US20190336198A1 (en) | 2018-05-03 | 2019-11-07 | Farapulse, Inc. | Systems, devices, and methods for ablation using surgical clamps |
| CN112118798B (zh) | 2018-05-07 | 2024-09-20 | 波士顿科学医学有限公司 | 用于过滤由脉冲电场消融诱导的高压噪声的系统、设备和方法 |
| EP3790486A1 (en) | 2018-05-07 | 2021-03-17 | Farapulse, Inc. | Systems, apparatuses and methods for delivery of ablative energy to tissue |
| EP3790485B1 (en) | 2018-05-07 | 2024-06-26 | Boston Scientific Scimed, Inc. | Epicardial ablation catheter |
| US11850398B2 (en) | 2018-08-01 | 2023-12-26 | Trisalus Life Sciences, Inc. | Systems and methods for pressure-facilitated therapeutic agent delivery |
| EP3852661A1 (en) | 2018-09-20 | 2021-07-28 | Farapulse, Inc. | Systems, apparatuses, and methods for delivery of pulsed electric field ablative energy to endocardial tissue |
| US11338117B2 (en) | 2018-10-08 | 2022-05-24 | Trisalus Life Sciences, Inc. | Implantable dual pathway therapeutic agent delivery port |
| US11564692B2 (en) | 2018-11-01 | 2023-01-31 | Terumo Corporation | Occlusion systems |
| US12433597B2 (en) | 2019-06-04 | 2025-10-07 | Trisalus Life Sciences, Inc. | Atraumatic occlusive system with compartment for measurement of vascular pressure change |
| JP2022545218A (ja) | 2019-08-20 | 2022-10-26 | エンボルクス，インク． | カテーテル、製造方法及び使用方法 |
| JP7411692B2 (ja) | 2019-08-26 | 2024-01-11 | ボストン サイエンティフィック サイムド，インコーポレイテッド | カテーテル付属品のための装置、システム及び方法 |
| US10625080B1 (en) | 2019-09-17 | 2020-04-21 | Farapulse, Inc. | Systems, apparatuses, and methods for detecting ectopic electrocardiogram signals during pulsed electric field ablation |
| US11065047B2 (en) | 2019-11-20 | 2021-07-20 | Farapulse, Inc. | Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses |
| US11497541B2 (en) | 2019-11-20 | 2022-11-15 | Boston Scientific Scimed, Inc. | Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses |
| US10842572B1 (en) | 2019-11-25 | 2020-11-24 | Farapulse, Inc. | Methods, systems, and apparatuses for tracking ablation devices and generating lesion lines |
| KR20230016048A (ko) | 2020-04-28 | 2023-01-31 | 테루모 코퍼레이션 | 폐색 시스템 |
| US12310652B2 (en) | 2020-07-24 | 2025-05-27 | Boston Scientific Scimed, Inc. | Hybrid electroporation ablation catheter |
| CN116209406A (zh) | 2020-07-24 | 2023-06-02 | 波士顿科学医学有限公司 | 不可逆电穿孔单次心脏消融的电场应用 |
| JP7617250B2 (ja) | 2020-09-08 | 2025-01-17 | ボストン サイエンティフィック サイムド，インコーポレイテッド | パルス電界アブレーションのための輪郭成形電極、ならびにそのシステム、デバイス、および方法 |
| WO2022072385A2 (en) | 2020-09-30 | 2022-04-07 | Boston Scientific Scimed Inc | Pretreatment waveform for irreversible electroporation |
| EP4284276A1 (en) | 2021-01-27 | 2023-12-06 | Boston Scientific Scimed, Inc. | Voltage controlled pulse sequences for irreversible electroporation ablations |
| US12453842B2 (en) | 2021-07-02 | 2025-10-28 | Embolx, Inc. | Catheters adapted for agent delivery |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US267407A (en) * | 1882-11-14 | Return-flue vertical boiler | ||
| DE3235974A1 (de) * | 1981-11-24 | 1983-06-01 | Volkmar Dipl.-Ing. Merkel (FH), 8520 Erlangen | Vorrichtung zur entfernung bzw. zur aufweitung von engstellen in koerperfluessigkeit fuehrenden gefaessen |
| US4636195A (en) * | 1982-04-02 | 1987-01-13 | Harvey Wolinsky | Method and apparatus for removing arterial constriction |
| US4714460A (en) * | 1983-07-29 | 1987-12-22 | Reynaldo Calderon | Methods and systems for retrograde perfusion in the body for curing it of the disease or immume deficiency |
| US4824436A (en) * | 1985-04-09 | 1989-04-25 | Harvey Wolinsky | Method for the prevention of restenosis |
| US4708718A (en) * | 1985-07-02 | 1987-11-24 | Target Therapeutics | Hyperthermic treatment of tumors |
| US4696668A (en) * | 1985-07-17 | 1987-09-29 | Wilcox Gilbert M | Double balloon nasobiliary occlusion catheter for treating gallstones and method of using the same |
| US4655746A (en) * | 1985-12-02 | 1987-04-07 | Target Therapeutics | Catheter device |
| JPS62236560A (ja) * | 1986-04-09 | 1987-10-16 | テルモ株式会社 | 血管修復用カテ−テル |
| US5328471A (en) * | 1990-02-26 | 1994-07-12 | Endoluminal Therapeutics, Inc. | Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens |
| US5160321A (en) * | 1988-11-23 | 1992-11-03 | Harvinder Sahota | Balloon catheters |
| US5674192A (en) * | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
| US5439446A (en) * | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
| US5176638A (en) * | 1990-01-12 | 1993-01-05 | Don Michael T Anthony | Regional perfusion catheter with improved drug delivery control |
| US5222941A (en) * | 1990-01-12 | 1993-06-29 | Don Michael T Anthony | Method of dissolving an obstruction in a vessel |
| US5163905A (en) * | 1990-01-12 | 1992-11-17 | Don Michael T Anthony | Regional perfusion dissolution catheter |
| US5090960A (en) * | 1990-01-12 | 1992-02-25 | Don Michael T Anthony | Regional perfusion dissolution catheter |
| US5460610A (en) * | 1990-01-12 | 1995-10-24 | Don Michael; T. Anthony | Treatment of obstructions in body passages |
| US5516336A (en) * | 1990-02-07 | 1996-05-14 | Advanced Cardiovascular Systems, Inc. | Readily exchangeable perfusion dilatation catheter |
| EP0533816B1 (en) * | 1990-06-15 | 1995-06-14 | Cortrak Medical, Inc. | Drug delivery apparatus |
| CA2074304C (en) * | 1991-08-02 | 1996-11-26 | Cyril J. Schweich, Jr. | Drug delivery catheter |
| EP0642368B1 (en) * | 1992-04-06 | 1999-01-27 | Angeion Corporation | Apparatus for treatment of ventricular tachycardia using a far-field pulse series |
| US5257634A (en) * | 1992-07-16 | 1993-11-02 | Angeion Corporation | Low impedence defibrillation catheter electrode |
| US5265623A (en) * | 1992-07-16 | 1993-11-30 | Angeion Corporation | Optimized field defibrillation catheter |
| US5454839A (en) * | 1992-07-27 | 1995-10-03 | Angeion Corporation | Low profile defibrillation catheter |
| US5649974A (en) * | 1992-07-27 | 1997-07-22 | Angeion Corporation | Low profile defibrillation catheter |
| US5256141A (en) * | 1992-12-22 | 1993-10-26 | Nelson Gencheff | Biological material deployment method and apparatus |
| US5599307A (en) * | 1993-07-26 | 1997-02-04 | Loyola University Of Chicago | Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities |
| US5409495A (en) * | 1993-08-24 | 1995-04-25 | Advanced Cardiovascular Systems, Inc. | Apparatus for uniformly implanting a stent |
| WO1995008289A2 (en) * | 1993-09-16 | 1995-03-30 | Scimed Life Systems, Inc. | Percutaneous repair of cardiovascular anomalies and repair compositions |
| US5462529A (en) * | 1993-09-29 | 1995-10-31 | Technology Development Center | Adjustable treatment chamber catheter |
| US5792106A (en) * | 1993-12-02 | 1998-08-11 | Scimed Life Systems, Inc. | In situ stent forming catheter |
| US5470313A (en) * | 1994-02-24 | 1995-11-28 | Cardiovascular Dynamics, Inc. | Variable diameter balloon dilatation catheter |
| US5415636A (en) * | 1994-04-13 | 1995-05-16 | Schneider (Usa) Inc | Dilation-drug delivery catheter |
| US5925066A (en) * | 1995-10-26 | 1999-07-20 | Galvani, Ltd. | Atrial arrythmia sensor with drug and electrical therapy control apparatus |
| US5728068A (en) | 1994-06-14 | 1998-03-17 | Cordis Corporation | Multi-purpose balloon catheter |
| US5514092A (en) * | 1994-08-08 | 1996-05-07 | Schneider (Usa) Inc. | Drug delivery and dilatation-drug delivery catheters in a rapid exchange configuration |
| US5569197A (en) * | 1994-12-21 | 1996-10-29 | Schneider (Usa) Inc | Drug delivery guidewire |
| US5749851A (en) * | 1995-03-02 | 1998-05-12 | Scimed Life Systems, Inc. | Stent installation method using balloon catheter having stepped compliance curve |
| US5674198A (en) * | 1995-06-23 | 1997-10-07 | Cordis Corporation | Tandem balloon catheter |
| US5785679A (en) * | 1995-07-19 | 1998-07-28 | Endotex Interventional Systems, Inc. | Methods and apparatus for treating aneurysms and arterio-venous fistulas |
| US5713944A (en) * | 1996-02-13 | 1998-02-03 | Angeion Corporation | Cardioversion-defibrillation catheter lead having selectively exposable outer conductors |
| US5925054A (en) * | 1996-02-20 | 1999-07-20 | Cardiothoracic Systems, Inc. | Perfusion device for maintaining blood flow in a vessel while isolating an anastomosis |
| US6022336A (en) * | 1996-05-20 | 2000-02-08 | Percusurge, Inc. | Catheter system for emboli containment |
| US5980514A (en) * | 1996-07-26 | 1999-11-09 | Target Therapeutics, Inc. | Aneurysm closure device assembly |
| US6291582B1 (en) * | 1996-10-10 | 2001-09-18 | Biotechnology Research & Development Corp. | Polymer-protein composites and methods for their preparation and use |
| US5868719A (en) * | 1997-01-15 | 1999-02-09 | Boston Scientific Corporation | Drug delivery balloon catheter device |
| US6039757A (en) * | 1997-03-12 | 2000-03-21 | Cardiosynopsis, Inc. | In situ formed fenestrated stent |
| US6132397A (en) | 1997-05-01 | 2000-10-17 | Chase Medical Inc. | Integral aortic arch infusion clamp catheter |
| US6056721A (en) * | 1997-08-08 | 2000-05-02 | Sunscope International, Inc. | Balloon catheter and method |
| US6015414A (en) * | 1997-08-29 | 2000-01-18 | Stereotaxis, Inc. | Method and apparatus for magnetically controlling motion direction of a mechanically pushed catheter |
| US20010041862A1 (en) * | 1997-09-02 | 2001-11-15 | Morton G. Glickman | Novel apparatus and method of treating a tumor in the extremity of a patient |
| EP0920882A3 (en) | 1997-12-04 | 2000-01-05 | Schneider Inc. | Balloon dilatation-drug delivery catheter and stent deployment-drug delivery catheter in rapid exchange configuration |
| US6027510A (en) * | 1997-12-08 | 2000-02-22 | Inflow Dynamics Inc. | Stent delivery system |
| US6695864B2 (en) * | 1997-12-15 | 2004-02-24 | Cardeon Corporation | Method and apparatus for cerebral embolic protection |
| US6254563B1 (en) * | 1997-12-15 | 2001-07-03 | Cardeon Corporation | Perfusion shunt apparatus and method |
| DE69818302D1 (de) * | 1997-12-15 | 2003-10-23 | Cardeon Corp | Perfusionsverbindungsvorrichtung |
| US6171296B1 (en) * | 1998-04-28 | 2001-01-09 | Microtherapeutics, Inc. | Flow directed catheter |
| US6132426A (en) * | 1998-05-05 | 2000-10-17 | Daig Corporation | Temperature and current limited ablation catheter |
| US6287306B1 (en) * | 1998-06-22 | 2001-09-11 | Daig Corporation | Even temperature linear lesion ablation catheter |
| US6136011A (en) * | 1998-07-14 | 2000-10-24 | Advanced Cardiovascular Systems, Inc. | Stent delivery system and method of use |
| US6290689B1 (en) * | 1999-10-22 | 2001-09-18 | Corazón Technologies, Inc. | Catheter devices and methods for their use in the treatment of calcified vascular occlusions |
| US6231588B1 (en) * | 1998-08-04 | 2001-05-15 | Percusurge, Inc. | Low profile catheter for angioplasty and occlusion |
| US6219582B1 (en) * | 1998-12-30 | 2001-04-17 | Daig Corporation | Temporary atrial cardioversion catheter |
| US6299599B1 (en) * | 1999-02-19 | 2001-10-09 | Alsius Corporation | Dual balloon central venous line catheter temperature control system |
| US6428558B1 (en) * | 1999-03-10 | 2002-08-06 | Cordis Corporation | Aneurysm embolization device |
| US6366808B1 (en) * | 2000-03-13 | 2002-04-02 | Edward A. Schroeppel | Implantable device and method for the electrical treatment of cancer |
| US7412285B2 (en) * | 1999-04-09 | 2008-08-12 | Oncostim, Inc. | Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
| US6738663B2 (en) * | 1999-04-09 | 2004-05-18 | Oncostim, A Minnesota Corporation | Implantable device and method for the electrical treatment of cancer |
| US6290673B1 (en) * | 1999-05-20 | 2001-09-18 | Conor Medsystems, Inc. | Expandable medical device delivery system and method |
| JP4841788B2 (ja) * | 2000-02-04 | 2011-12-21 | コンメド エンドスコピック テクノロジーズ インコーポレイテッド | ３管腔結石バルーン・カテーテルおよびその方法 |
| ATE373682T1 (de) * | 2000-03-13 | 2007-10-15 | Biocure Inc | Embolische zusammensetzungen |
| US7742811B2 (en) * | 2000-03-13 | 2010-06-22 | Onco Stim | Implantable device and method for the electrical treatment of cancer |
| US6679879B2 (en) * | 2000-08-16 | 2004-01-20 | John H. Shadduck | Electrical discharge catheter system for extracting emboli in endovascular interventions |
| JP4705715B2 (ja) | 2000-09-29 | 2011-06-22 | クリエートメディック株式会社 | バルーンカテーテル |
| US6692458B2 (en) * | 2000-12-19 | 2004-02-17 | Edwards Lifesciences Corporation | Intra-pericardial drug delivery device with multiple balloons and method for angiogenesis |
| US6582448B1 (en) * | 2000-12-21 | 2003-06-24 | Advanced Cardiovascular Systems, Inc. | Vessel occlusion device for embolic protection system |
| US6746465B2 (en) * | 2001-12-14 | 2004-06-08 | The Regents Of The University Of California | Catheter based balloon for therapy modification and positioning of tissue |
| US20050267407A1 (en) | 2002-02-01 | 2005-12-01 | Vascular Designs, Inc. | Multi-function catheter and use thereof |
| US8062251B2 (en) * | 2002-02-01 | 2011-11-22 | Vascular Designs, Inc. | Multi-function catheter and use thereof |
| CA2476263C (en) * | 2002-02-01 | 2012-08-21 | Robert J. Goldman | Multi-function catheter and use thereof |
| US7144407B1 (en) * | 2002-05-30 | 2006-12-05 | Alsius Corporation | Cardiovascular intra aortic balloon pump catheter with heat exchange function and methods of use |
| US6835189B2 (en) * | 2002-10-15 | 2004-12-28 | Scimed Life Systems, Inc. | Controlled deployment balloon |
| US20070137651A1 (en) * | 2005-12-16 | 2007-06-21 | Ezc Medical Llc | Visualization esophageal-tracheal airway apparatus and methods |
-
2008
- 2008-01-09 US US11/971,859 patent/US8062251B2/en not_active Expired - Fee Related
-
2009
- 2009-01-08 JP JP2010542338A patent/JP2011509158A/ja active Pending
- 2009-01-08 CA CA2711739A patent/CA2711739A1/en not_active Abandoned
- 2009-01-08 EP EP09701443.5A patent/EP2240231A4/en not_active Withdrawn
- 2009-01-08 WO PCT/US2009/030434 patent/WO2009089343A1/en not_active Ceased
- 2009-03-17 US US12/405,592 patent/US8251948B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2240231A4 (en) | 2013-06-05 |
| EP2240231A1 (en) | 2010-10-20 |
| JP2011509158A (ja) | 2011-03-24 |
| US20090182227A1 (en) | 2009-07-16 |
| US20080208118A1 (en) | 2008-08-28 |
| US8251948B2 (en) | 2012-08-28 |
| US8062251B2 (en) | 2011-11-22 |
| WO2009089343A1 (en) | 2009-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8062251B2 (en) | Multi-function catheter and use thereof | |
| CA2476263C (en) | Multi-function catheter and use thereof | |
| US20050267407A1 (en) | Multi-function catheter and use thereof | |
| EP0767685B1 (en) | Catheter assembly | |
| US8932326B2 (en) | Method and apparatus for repairing vascular abnormalities and/or other body lumen abnormalities using an endoluminal approach and a flowable forming material | |
| EP2344230B1 (en) | Occlusion perfusion catheter | |
| US5857998A (en) | Stent and therapeutic delivery system | |
| EP2313146B1 (en) | Devices for the treatment of vascular aneurysm | |
| EP1913882A1 (en) | Flexible and rigid catherer resector balloon | |
| JPH06501165A (ja) | 中空の器管およびその他の組織管腔における病巣を処置する装置 | |
| JP2022527295A (ja) | 血管内グラフトに関連する処置のための方法及びデバイス | |
| JPH09504212A (ja) | 生体管内の障害を治療する方法 | |
| WO2009036118A1 (en) | Drug eluting balloon | |
| CN108784895B (zh) | 一种扩张支架系统 | |
| WO2007076324A2 (en) | Balloon catheter with centralized vent hole | |
| HK1200130B (en) | Occlusion perfusion catheter | |
| HK1230995A1 (en) | Occlusion perfusion catheter | |
| HK1160046B (en) | Occlusion perfusion catheter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20150108 |